secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001140361-24-046015
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q2 loss $236.8M; Dermavant deal closed; cash $5.4B; brepocitinib NIU data
--------------------------------------------------------------------------------

- Q2 loss from continuing ops $236.8M ($0.25 EPS); R&D $143.1M; G&A $202.9M up $114.3M YoY on retention awards.
- Dermavant transaction closed Oct 28: Roivant received $184M cash; Organon assumed $336M debt; $75M milestone pending VTAMA FDA approval for atopic dermatitis.
- Consolidated cash, cash equivalents and marketable securities ~$5.4B at Sep 30, 2024.
- Share repurchases $106M in Q2; cumulative $754M (incl. Sumitomo stake buyback).
- Pipeline: brepocitinib Phase 2 NIU 52-wk data shows sustained efficacy; batoclimab GD 76% response; mosliciguat PVR reduction ~38%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/0001140361-24-046015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer